ESKKF yields 581.56% · JNJ yields 2.13%● Live data
📍 ESKKF pulled ahead of the other in Year 1
Combined, ESKKF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ESKKF + JNJ for your $10,000?
Etherstack plc, a wireless technology company, engages in licensing mission critical radio technologies to equipment manufacturers and network operators Australia and internationally. Its technology enables push-to-talk (PTT) communications; and advanced digital land mobile radio (LMR), and cellular and satellite networks. The company offers a range of cryptographic solutions, including P25 Security Suite unites AES/DES P25 encryption engine with P25 key fill device (KFD) support for complete P25 subscriber encryption; P25 key management facility; P25 security dongles; and FIPS 140-2 Cryptographic Module, a single-board security device that implements APCO P25 encryption, decryption, and key management and storage services in conformance with FIPS140-2 standards. It also provides defense waveforms, such as technology licensing and transfer, and specialist services; waveform heritage; waveform test and development environment; outsource your risks; and reconfiguration and framework architecture standards. In addition, the company offers LMR network building blocks; APCO P25, dPMR, DMR, MPT1327, and TETRA wireless communications protocol stacks; and tactical and satellite solutions comprising P25 tactical repeaters and IVX PTT IP radio. It serves public safety, defense, utilities, transportation, and resource sectors. The company was formerly known as MM&S (5698) plc and changed its name to Etherstack plc in May 2012. Etherstack plc was incorporated in 2012 and is based in Chippendale, Australia.
Full ESKKF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.